KR102593783B1 - 결정성 화합물 - Google Patents

결정성 화합물 Download PDF

Info

Publication number
KR102593783B1
KR102593783B1 KR1020187001083A KR20187001083A KR102593783B1 KR 102593783 B1 KR102593783 B1 KR 102593783B1 KR 1020187001083 A KR1020187001083 A KR 1020187001083A KR 20187001083 A KR20187001083 A KR 20187001083A KR 102593783 B1 KR102593783 B1 KR 102593783B1
Authority
KR
South Korea
Prior art keywords
crystal form
xrpd
radiation
formulas
measured
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187001083A
Other languages
English (en)
Korean (ko)
Other versions
KR20180014830A (ko
Inventor
앤소니 알렉산더 맥키니
프랭클린 바이마스터
월터 피스코르스키
프레드 제이. 플라이츠
융라이 양
데이비드 에이. 엥어스
발레리야 스몰렌스카야
벤캇 쿠스쿤틀라
Original Assignee
오츠카 아메리카 파마슈티컬, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 오츠카 아메리카 파마슈티컬, 인코포레이티드 filed Critical 오츠카 아메리카 파마슈티컬, 인코포레이티드
Publication of KR20180014830A publication Critical patent/KR20180014830A/ko
Application granted granted Critical
Publication of KR102593783B1 publication Critical patent/KR102593783B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/16—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings other than six-membered aromatic rings
    • C07C211/17—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings other than six-membered aromatic rings containing only non-condensed rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
KR1020187001083A 2015-06-17 2016-06-17 결정성 화합물 Active KR102593783B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562181174P 2015-06-17 2015-06-17
US62/181,174 2015-06-17
PCT/US2016/038256 WO2016205762A1 (en) 2015-06-17 2016-06-17 Crystalline compounds

Publications (2)

Publication Number Publication Date
KR20180014830A KR20180014830A (ko) 2018-02-09
KR102593783B1 true KR102593783B1 (ko) 2023-10-25

Family

ID=57546597

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187001083A Active KR102593783B1 (ko) 2015-06-17 2016-06-17 결정성 화합물

Country Status (25)

Country Link
US (5) US9708261B2 (enExample)
EP (3) EP4049997A1 (enExample)
JP (4) JP6896651B2 (enExample)
KR (1) KR102593783B1 (enExample)
CN (3) CN107921021A (enExample)
AU (2) AU2016279075C1 (enExample)
CA (2) CA3200692A1 (enExample)
CY (1) CY1125352T1 (enExample)
DK (1) DK3597189T3 (enExample)
ES (1) ES2922158T3 (enExample)
HK (1) HK1247125A1 (enExample)
HR (1) HRP20220829T1 (enExample)
HU (1) HUE059348T2 (enExample)
LT (1) LT3597189T (enExample)
MX (2) MX387591B (enExample)
MY (1) MY194868A (enExample)
NZ (2) NZ776973A (enExample)
PH (1) PH12017502324A1 (enExample)
PL (1) PL3597189T3 (enExample)
PT (1) PT3597189T (enExample)
SA (1) SA517390552B1 (enExample)
SG (1) SG10201911417PA (enExample)
SI (1) SI3597189T1 (enExample)
TW (1) TWI751998B (enExample)
WO (1) WO2016205762A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101272781A (zh) 2005-07-27 2008-09-24 多夫药品公司 新的1-芳基-3-氮杂二环[3.1.0]己烷：其制备方法和用于治疗神经精神障碍的用途
US20140206740A1 (en) 2011-07-30 2014-07-24 Neurovance, Inc. Use Of (1R,5S)-(+)-(Napthalen-2-yl)-3-Azabicyclo[3.1.0]Hexane In The Treatment Of Conditions Affected By Monoamine Neurotransmitters
US20160303077A1 (en) 2013-12-09 2016-10-20 Neurovance, Inc. Novel compositions
CN107921021A (zh) 2015-06-17 2018-04-17 大塚制药美国公司 结晶化合物
CN111417624B (zh) * 2017-12-11 2022-03-25 苏州科睿思制药有限公司 Eb-1020的晶型及其制备方法和用途
WO2021075494A1 (ja) 2019-10-16 2021-04-22 大塚製薬株式会社 センタナファジンの製造方法
WO2022256215A1 (en) 2021-05-31 2022-12-08 Teva Pharmaceuticals International Gmbh Solid state form of centanafadine hcl and process for preparation thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013019271A1 (en) * 2011-07-30 2013-02-07 Neurovance, Inc. Use of (1r,5s)-(+)-1-(naphthalen-2-yl)-3-azabicyclo{3.1.0}hexane in the treatment of conditions affected by monoamine neurotransmitters

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7094799B2 (en) 2002-11-08 2006-08-22 Dov Pharmaceutical, Inc. Polymorphs of bicifadine hydrochloride
EP1740593B1 (en) 2004-04-19 2016-04-06 KRKA, tovarna zdravil, d.d., Novo mesto Processes for the preparation of clopidogrel hydrogen sulfate polymorphic form i
US20070043100A1 (en) 2005-08-16 2007-02-22 Hagen Eric J Novel polymorphs of azabicyclohexane
ZA200701570B (en) 2004-08-18 2008-08-27 Dov Pharmaceutical Inc Novel polymorphs of azabicyclohexane
US20070082939A1 (en) 2005-07-26 2007-04-12 Lippa Arnold S Methods and compositions for the treatment of neuropathies and related disorders
CN101272781A (zh) 2005-07-27 2008-09-24 多夫药品公司 新的1-芳基-3-氮杂二环[3.1.0]己烷：其制备方法和用于治疗神经精神障碍的用途
US7919598B2 (en) 2006-06-28 2011-04-05 Bristol-Myers Squibb Company Crystal structures of SGLT2 inhibitors and processes for preparing same
US20080058535A1 (en) * 2006-07-25 2008-03-06 Zhengming Chen Methods and compositions for production, formulation and use of 1 aryl-3-azabicyclo[3.1.0]hexanes
US8576985B2 (en) 2009-09-01 2013-11-05 Aptuit (West Lafayette) Llc Methods for indexing solid forms of compounds
CN103476770B (zh) * 2010-11-25 2017-02-15 拉蒂欧制药有限责任公司 阿法替尼盐和多晶型物
US20140206740A1 (en) 2011-07-30 2014-07-24 Neurovance, Inc. Use Of (1R,5S)-(+)-(Napthalen-2-yl)-3-Azabicyclo[3.1.0]Hexane In The Treatment Of Conditions Affected By Monoamine Neurotransmitters
US20140228421A1 (en) 2011-09-07 2014-08-14 Anthony McKinney Methods For Inhibiting Native And Promiscuous Uptake Of Monoamine Neurotransmitters
US20160303077A1 (en) 2013-12-09 2016-10-20 Neurovance, Inc. Novel compositions
CN107921021A (zh) 2015-06-17 2018-04-17 大塚制药美国公司 结晶化合物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013019271A1 (en) * 2011-07-30 2013-02-07 Neurovance, Inc. Use of (1r,5s)-(+)-1-(naphthalen-2-yl)-3-azabicyclo{3.1.0}hexane in the treatment of conditions affected by monoamine neurotransmitters

Also Published As

Publication number Publication date
AU2016279075B2 (en) 2020-10-22
US20210198198A1 (en) 2021-07-01
RU2018101244A (ru) 2019-07-22
CA2989431A1 (en) 2016-12-22
US20170334850A1 (en) 2017-11-23
EP3597189A1 (en) 2020-01-22
HK1247125A1 (zh) 2018-09-21
EP3597189B1 (en) 2022-06-01
US20200039934A1 (en) 2020-02-06
ES2922158T3 (es) 2022-09-09
RU2018101244A3 (enExample) 2019-12-23
EP4049997A1 (en) 2022-08-31
MX2017016430A (es) 2018-11-09
WO2016205762A1 (en) 2016-12-22
AU2016279075A1 (en) 2018-02-01
JP2018517742A (ja) 2018-07-05
CN107921021A (zh) 2018-04-17
JP7244575B2 (ja) 2023-03-22
US9708261B2 (en) 2017-07-18
HRP20220829T1 (hr) 2022-12-23
US10800740B2 (en) 2020-10-13
DK3597189T3 (da) 2022-06-27
CA2989431C (en) 2023-08-29
AU2021200314A1 (en) 2021-03-18
CA3200692A1 (en) 2016-12-22
US20160368871A1 (en) 2016-12-22
JP7583851B2 (ja) 2024-11-14
PL3597189T3 (pl) 2022-07-25
KR20180014830A (ko) 2018-02-09
NZ776973A (en) 2022-11-25
AU2021200314B2 (en) 2022-08-04
TWI751998B (zh) 2022-01-11
TW201800392A (zh) 2018-01-01
US10280141B2 (en) 2019-05-07
CY1125352T1 (el) 2025-05-09
JP2021138747A (ja) 2021-09-16
PH12017502324A1 (en) 2018-06-25
JP2023071978A (ja) 2023-05-23
LT3597189T (lt) 2022-07-11
US11299458B2 (en) 2022-04-12
AU2016279075C1 (en) 2021-04-01
MY194868A (en) 2022-12-21
NZ739044A (en) 2022-08-26
US20180194726A1 (en) 2018-07-12
US9856217B2 (en) 2018-01-02
SI3597189T1 (sl) 2022-08-31
JP2025022896A (ja) 2025-02-14
PT3597189T (pt) 2022-07-05
MX387591B (es) 2025-03-18
HUE059348T2 (hu) 2022-11-28
EP3310352A4 (en) 2019-03-13
EP3310352A1 (en) 2018-04-25
SG10201911417PA (en) 2020-01-30
CN117088802A (zh) 2023-11-21
MX2020009949A (es) 2020-10-16
SA517390552B1 (ar) 2022-04-13
JP6896651B2 (ja) 2021-06-30
CN117466800A (zh) 2024-01-30

Similar Documents

Publication Publication Date Title
KR102593783B1 (ko) 결정성 화합물
AU2012306386B2 (en) Polymorphic form of pridopidine hydrochloride
JP2018517742A5 (enExample)
JP7303821B2 (ja) ピリミジニルアミノ－ピラゾール化合物の多形体及び固体形態、ならびに製造方法
RU2789672C2 (ru) Кристаллические соединения
WO2018119291A1 (en) Synthetic methods
HK40077679A (en) Crystalline compounds
HK40020220A (en) Crystalline compounds
HK40020220B (en) Crystalline compounds

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601